eli lilly glp 1 agonist Abu Dhabi, United Arab Emirates – and Company (NYSE: LLY) today reported positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an investigational oral GLP-1 receptor agonist, in StockWatch: Investors Hammer Lilly as
Pay in 4 interest-free payments of $6.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
























